-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2015 to Q1 2025.
- Adaptimmune Therapeutics PLC Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$25.3M, a 187% decline year-over-year.
- Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Financing Activities for 2024 was $78.7M, a 8849% increase from 2023.
- Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $880K, a 93.2% decline from 2022.
- Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Financing Activities for 2022 was $12.9M, a 291% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)